LabCorp Backs Resolution Bioscience’s Liquid Biopsy Test for NSCLC
XTalks
SEPTEMBER 28, 2020
The test is based on the detection of actionable genes – genes with known driver mutations that can be targeted by an approved therapy (or investigational therapies in clinical trials). The liquid biopsy will therefore help personalize medicines for patients based on the molecular features of their disease.
105 
Let's personalize your content